接受双膦酸盐治疗的多发性骨髓瘤患者的颌骨骨坏死：唑来膦酸治疗后风险增加的证据。
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
作者信息
Dimopoulos Meletios A, Kastritis Efstathios, Anagnostopoulos Athanasios, Melakopoulos Ioannis, Gika Dimitra, Moulopoulos Lia A, Bamia Christina, Terpos Evangelos, Tsionos Konstantinos, Bamias Aristotelis
机构信息
Dept of Clinical Therapeutics, Medical School, University of Athens, Greece.
出版信息
Haematologica. 2006 Jul;91(7):968-71. Epub 2006 Jun 1.
Osteonecrosis of the jaw (ONJ) has been associated with the use of pamidronate and zoledronic acid. ONJ was assessed prospectively since July 2003 in 202 patients with multiple myeloma (MM) who received bisphosphonates since April 1995. Fifteen patients (7.4%) developed ONJ. The median time of exposure to bisphosphonates was 39 months for patients with ONJ compared to 28 months (p=0.048) for patients with no ONJ. The cumulative hazard of developing ONJ was significantly higher in patients treated with zoledronic acid alone than in those treated with pamidronate alone/pamidronate+zoledronic acid/zoledronic acid+ibandronate sequentially (1% at 1 year and 15% at 4 years vs. 0% and 5%, p=0.003). In conclusion, the risk of ONJ is increased with time of exposure and probably with the use of zoledronic acid.
颌骨骨坏死（ONJ）与帕米膦酸盐和唑来膦酸的使用有关。自2003年7月起，对自1995年4月起接受双膦酸盐治疗的202例多发性骨髓瘤（MM）患者进行了前瞻性ONJ评估。15例患者（7.4%）发生了ONJ。发生ONJ的患者接触双膦酸盐的中位时间为39个月，而未发生ONJ的患者为28个月（p=0.048）。单独使用唑来膦酸治疗的患者发生ONJ的累积风险显著高于单独使用帕米膦酸盐/帕米膦酸盐+唑来膦酸/唑来膦酸+伊班膦酸钠序贯治疗的患者（1年时为1%，4年时为15%，而后者为0%和5%，p=0.003）。总之，ONJ的风险随着接触时间的延长而增加，可能也与唑来膦酸的使用有关。
Zotero 插件